QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
EASL 2026: Key takeaways from Barcelona
Last week, our colleague Alexandra Wennberg represented Quantify Research at EASL 2026, joining leading researchers, clinicians, and industry experts to discuss the latest advances in liver disease research and patient care.
Several themes stood out across the congress:
• Progress towards a functional cure for hepatitis B, with promising Phase 3 results generating considerable interest
• Continued momentum in MASH, as new evidence further […]
EASL 2026
Great to see our colleague Alexandra Wennberg attending EASL this week and engaging in discussions on the latest developments in liver disease research, real-world evidence, and patient outcomes📊
Conferences like EASL are an important reminder of how quickly the evidence landscape evolves and how valuable cross-disciplinary dialogue remains for translating science into better decision-making.
If you are attending EASL, Alexandra would be happy to connect and exchange perspectives.
[…]
Finland may be a small market but it requires deep market access expertise.
Our team in Finland has grown significantly this year, and for that, we owe a huge thank you to our excellent clients and the outstanding work delivered by our consultants.
Our Finnish Modelling, Access & Strategy team combines extensive experience from the pharmaceutical industry, consulting, and life sciences. Together, this team brings close to 60 years of expertise across these areas: Katja Nolvi Sami Gabbouj Petri Niinisalo, PhD Ville Perälä
Our […]
EASL 2026 | Barcelona
Alexandra Wennberg is on her way to Barcelona for the EASL 2026 Congress ✈️
Over the coming days, she will meet clients and colleagues to discuss real-world evidence in liver disease and share perspectives from the Quantify Research Liver Disease Platform.
Nordic registry data continues to offer unique opportunities for long-term hepatology research — particularly where clinical depth and longitudinal follow-up matter most.
If you are attending EASL and would like to […]
